Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 17,019

Document Document Title
WO/2009/123174A1
A medicinal preparation for patients having a neutralizing antibody against a botulinum toxin originating in a Clostridium botulinum type A1 strain (type A1 botulinum toxin) characterized by comprising as the active ingredient a 150 kDa ...  
WO/2009/121623A3
Compounds of formula (I): wherein X, L1, R1, L2, R2, R3, and R4 are as defined herein, are useful in the treatment or prophylaxis of Duchenne muscular dystrophy, Becker muscular dystrophy, or cachexia.  
WO/2009/123221A1
Disclosed is a prophylactic or therapeutic agent for nerve diseases such as ischemic brain diseases and neurodegenerative diseases or the like or a prophylactic or therapeutic agent for diseases for which an antioxidant activity is effec...  
WO/2009/120815A9  
WO/2009/120304A1
Agonists of a non-proteolytically activated thrombin receptor, and more particularly, thrombin peptide derivatives, can be used in methods to cause smooth muscle relaxation. Compositions comprising thrombin peptide derivatives can be adm...  
WO/2009/120815A2  
WO/2009/115321A8
The present invention relates to substituted imidazopyrimidine derivatives, substituted imidazopyrazine derivatives and substituted imidazopyridazine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocorti...  
WO/2009/115321A1
The present invention relates to substituted imidazopyrimidine derivatives, substituted imidazopyrazine derivatives and substituted imidazopyridazine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocorti...  
WO/2009/114597A1
Compositions containing apoaequorin and methods for their use in treating symptoms and disorders related to calcium imbalances associated with, for example, sleep quality, energy quality, mood quality, memory quality or pain are provided...  
WO/2009/105691A3
Methods are provided herein for treatment of myotonic dystrophy and other toxic RNA diseases in a subject. In some examples, the method comprises administration of a compound that binds a nucleotide repeat expansion in a ribonucleic acid...  
WO/2009/104388A1
Disclosed is a prophylactic/therapeutic agent for collagenosis, which can inhibit the function of TREM-1 to exhibit a prophylactic/therapeutic effect on collagenosis. Also disclosed is a method for the screening of a prophylactic/therape...  
WO/2009/104807A1
In one embodiment, provided is a composition comprising a prostaglandin compound for modulating stem cell proliferation and/or differentiation in a mammalian subject. In another embodiment, the instant application is a composition compri...  
WO/2009/105691A2
Methods are provided herein for treatment of myotonic dystrophy and other toxic RNA diseases in a subject. In some examples, the method comprises administration of a compound that binds a nucleotide repeat expansion in a ribonucleic acid...  
WO/2009/101399A1
A method of correcting expression of a gene in a human cell having a muscle disease or muscular dystrophy phenotype, wherein without correction the gene fails to express functional protein due to one or more mutations, said method compri...  
WO/2009/101137A1
We disclose the use of 25-OH D3 (calcifediol) to increase muscle strength, muscle function, or both. Vitamin D3 (cholecalciferol) may optionally be used together with 25-OH D3. Forms and dosages of a pharmaceutical composition, as well a...  
WO/2009/099326A1
The current invention provides for methods and medicaments that apply an oligonucleotide comprising aninosine and/or an uracile and/or a nucleotide containing a base able to form a wobble base pair, said oligonucleotide being preferably ...  
WO/2009/098533A1
The present invention relates to the use of a non-immunosuppressive cyclosporin A derivative for preventing or reducing muscular degeneration in a subject suffering from Limb-Girdle muscular Dystrophy.  
WO/2009/098577A2
The present invention relates to the use of a non-immunosuppressive cyclosporin A derivative for preventing or reducing muscular degeneration in a subject suffering from Limb-Girdle muscular Dystrophy.  
WO/2009/098577A3
The present invention relates to the use of a non-immunosuppressive cyclosporin A derivative for preventing or reducing muscular degeneration in a subject suffering from Limb-Girdle muscular Dystrophy.  
WO/2009/095378A1
The invention provides methods for the diagnosis and treatment of musculoskeletal disorders relating to the Hedgehog pathway, including but not limited to muscular dystrophy (e.g., Duchenne Muscular Dystrophy) using agents that agonize S...  
WO/2009/079741A1
Mammalian cells express heat shock proteins (HSPs) in response to various stresses, such as exercise. Recent studies suggest that expression of heat shock proteins in general, and HSP72 in particular, play a role in muscular hypertrophy....  
WO/2009/079562A2
The present invention relates to compositions and methods for treating and preventing skeletal muscle deficiencies. In particular, the present invention provides compositions comprising poloxamers (e.g., poloxamer 188 - P188) and methods...  
WO/2009/079562A3
The present invention relates to compositions and methods for treating and preventing skeletal muscle deficiencies. In particular, the present invention provides compositions comprising poloxamers (e.g., poloxamer 188 - P188) and methods...  
WO/2009/073944A1
Disclosed is the use of pyridoxine α-hydroxyisocaproate for attenuating metabolic acidosis and decreasing ammonia accumulation in blood and muscle. As a result of this action, there is a reduction in central and muscular fatigue and a d...  
WO/2009/073947A1
The present invention relates to stable salts of β -alanine and an organic acid selected from the group consisting of malate, citrate and fumarate, endowed with enhanced nutritional and/or therapeutical efficacy in respect to their indi...  
WO/2009/073942A1
A nutritional composition comprising at least an effective amount of trigonelline or derivative of trigonelline and an effective amount of tropane alkaloids, wherein the ingredients act substantially simultaneously improve the consistenc...  
WO/2009/071405A1
The present invention relates to the treatment of patients suffering from cachexia as a comorbidity of cancer using megestrol acetate (MA), in particular using megestrol acetate oral suspension (MegaceTM), more precisely using the advanc...  
WO/2009/068689A2
The invention relates to the use of a combination of protein tyrosine phosphatase inhibitors and human growth hormone for the treatment of musculoskeletal diseases, particularly for the treatment of muscle atrophy.  
WO/2009/068689A3
The invention relates to the use of a combination of protein tyrosine phosphatase inhibitors and human growth hormone for the treatment of musculoskeletal diseases, particularly for the treatment of muscle atrophy.  
WO/2009/069736A1
Disclosed is a nitrogenated compound represented by the formula (I) [wherein A represents an aryl which may have a substituent or the like; B's independently represent a hydrogen atom, a halogen or the like; n represents an integer of no...  
WO/2009/065854A1
This invention relates to N-acylhydrazone derivatives (I), which are found to be useful as modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the tre...  
WO/2009/066457A1
Disclosed is an external preparation composition having good transdermal absorbability. An external preparation composition having excellent transdermal absorbability can be produced by dissolving a medicinal substance or a salt thereof ...  
WO/2009/062683A1
The present invention relates to novel uses of C-19 steroid compounds, in particular C-19 steroids having an androsten-17- (OR4)-3-one structure for prophylactic and/or therapeutic uses, wherein R4 is hydrogen or an unsubstituted or subs...  
WO/2009/063993A1
Disclosed is a serotonin 5-HT2c receptor activator containing a compound represented by the formula (I) below or a salt thereof. (In the formula, the symbols are as defined in the description.)  
WO/2009/057086A1
The present invention provides R,R'-atracurium salts, processes for producing and purifying such salts, and methods of using such salts to produce highly pure cisatracurium besylate.  
WO/2009/054501A1
Use of a carbon dioxide-supplying unit for muscle strengthening makes it possible conveniently strengthen a target muscle within a short period of time merely by allowing the target site to absorb carbon dioxide without loading any a mec...  
WO/2009/054725A2
The invention provides means and methods for alleviating one or more symptom(s) of Duchenne Muscular Dystrophy and/or Becker Muscular Dystrophy. Therapies using compounds for providing patients with functional muscle proteins are combine...  
WO/2009/054725A3
The invention provides means and methods for alleviating one or more symptom(s) of Duchenne Muscular Dystrophy and/or Becker Muscular Dystrophy. Therapies using compounds for providing patients with functional muscle proteins are combine...  
WO/2009/051244A1
Disclosed is a compound represented by the following formula (I). (In the formula, the symbols are as defined in the description.) This compound has an excellent RBP4 lowering effect, and is useful as an agent for prevention or treatment...  
WO/2009/044383A1
The present invention relates to a nucleic acid molecule comprising a nucleotide sequence codifying for a protein characterized in having at least four zinc finger domains and in modulating the transcription of the utrophin gene by bindi...  
WO/2009/044787A1
It is clarified that the inhibition of the expression or function of tenomodulin induces a disease relating to the rupture of a tendon such as CTC. It is expected that tenomodulin protein or a substance capable of activating the expressi...  
WO/2009/044383A8
The present invention relates to a nucleic acid molecule comprising a nucleotide sequence codifying for a protein characterized in having at least four zinc finger domains and in modulating the transcription of the utrophin gene by bindi...  
WO/2009/040814A1
The invention provides an active agent selected from the group consisting of Copolymer 1, a Copolymer 1 related-peptide and a Copolymer 1-related polypeptide, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions...  
WO/2009/042907A1
Disclosed is a compound of Formula (I) in which W and R1-R6 are defined herein. Also disclosed is a method of treating spinal muscular atrophy, as well as methods of using such compounds to increase SMN expression, increase EAAT2 express...  
WO/2009/036590A1
The present invention relates to novel compounds from Antrodia cinnamomea and their use.  
WO/2009/038110A1
Disclosed is a pharmaceutical agent having high safety and a neurotrophic factor-like activity, which comprises, as an active ingredient, any one compound included in fatty acids each having 8 carbon atoms (C8) or having 10 carbon atoms ...  
WO/2009/036149A9
A method for treating a degenerative disease or neurodegenerative disease in a mammalian subject is provided. The method provides administering VEGF-B polypeptide or functional variant or mimetic thereof in an amount effective to reduce ...  
WO/2009/036149A3
A method for treating a degenerative disease or neurodegenerative disease in a mammalian subject is provided. The method provides administering VEGF-B polypeptide or functional variant or mimetic thereof in an amount effective to reduce ...  
WO/2009/033250A1
A nutritional supplement comprising a therapeutically effective amount of ethyl pyruvate and a therapeutically effective amount of at least one α-hydroxy branched-chain amino acid metabolite is provided by the present invention. The ing...  
WO/2009/036149A2
A method for treating a degenerative disease or neurodegenerative disease in a mammalian subject is provided. The method provides administering VEGF-B polypeptide or functional variant or mimetic thereof in an amount effective to reduce ...  

Matches 701 - 750 out of 17,019